Tina Billberry
Family Medicine · Alexandria, LANPI 1437789203
Payments from drug & device makers
Across 282 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$904
- Lilly USA, LLC$566
- Novo Nordisk$494
- Amgen$269
- GSK$191
- plus $1K from 28 others
What the payments were for
- Food & beverage$5,356100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,499 |
| AstraZeneca | 35 | $904 |
| Lilly USA, LLC | 32 | $566 |
| Novo Nordisk | 33 | $494 |
| Amgen | 16 | $269 |
| GSK | 11 | $191 |
| Intuitive Surgical | 2 | $181 |
| Pfizer | 7 | $141 |
| Astellas Pharma US Inc | 3 | $120 |
| Bayer | 2 | $104 |
| Evoke Pharma, Inc. | 1 | $90 |
| Johnson & Johnson | 6 | $90 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 4 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Exact Sciences | 3 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $46 |
| Genentech USA, Inc. | 4 | $31 |
| Corium, LLC | 1 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Boston Scientific | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Boehringer Ingelheim | 2 | $25 |
| Averitas Pharma Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $19 |
| Novartis | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Corcept Therapeutics | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,356 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 52 | $75,285 |
| JardianceEmpagliflozin | 55 | $58,813 |
| FarxigaDapagliflozin Propanediol | 64 | $55,559 |
| RybelsusSemaglutide | 34 | $53,697 |
| EliquisApixaban | 32 | $37,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,300 |
| OzempicSemaglutide | 16 | $15,106 |
| LinzessLinaclotide | 12 | $14,809 |
| JanuviaSitagliptin Phosphate | 15 | $10,139 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $10,137 |
| Atorvastatin Calcium | 218 | $2,871 |
| Rosuvastatin Calcium | 60 | $1,952 |
| Levothyroxine Sodium | 183 | $1,828 |
| Diclofenac Sodium | 63 | $1,805 |
| Omeprazole | 168 | $1,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $566 | $75,28552 claims |
| Novo NordiskRybelsus, Ozempic | $494 | $68,80350 claims |
| Boehringer IngelheimJardiance | $25 | $58,81355 claims |
| AstraZenecaFarxiga | $904 | $55,55964 claims |
| PfizerEliquis | $141 | $37,21832 claims |
| GSKTrelegy Ellipta | $191 | $16,30024 claims |
| AbbVieLinzess, Synthroid | $1,499 | $15,53436 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $46 | $10,13712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Alexandria
- Michael ScrepetisAlexandria$27K
- Gregory BevelsAlexandria$24K
- Kenneth BrownAlexandria$17K
- Gregory BrianAlexandria$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.